shortagewatch

Home / Companies / Orifarm

Company family · HQ DK

Orifarm: medicine shortages

private

As of 2 Nov 2026, 59 Orifarm products have a reported shortage across 3 countries, covering 40 medicines.

Products short59rank #32 of 464
Medicines40active ingredients
Countries3/16
New in 90 days27+2 vs market pace
Typical duration3 monthsmedian so far
Manufacturing27%demand-driven 5%

Where

Belgium10Norway12Sweden37

Which therapeutic classes

Nervous system23Digestive tract and metabolism11Dermatologicals6Respiratory system4Musculoskeletal system3Blood2Cardiovascular system2Genito-urinary system and sex hormones2Various2Cancer and immune system2

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
OrifarmOrifarm: Manufacturing problem 6 (10%)10%Orifarm: Increased demand 1 (2%)Orifarm: Distribution or logistics 4 (7%)7%Orifarm: Commercial decision or withdrawal 2 (3%)Orifarm: Regulatory or licensing 4 (7%)7%Orifarm: Other 5 (8%)8%Orifarm: Not stated 37 (63%)63%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

05101520Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 1MayJun: 1Jul: 0Aug: 1AugSep: 1Oct: 1Nov: 1NovDec: 3Jan ’26: 1Feb: 1FebMar: 2Apr: 1May: 6MayJun: 3Jul: 5Aug: 4AugSep: 5Oct: 15Nov: 6Nov

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Orifarm59

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Orifarm: 59 / 40Orifarm

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Isotretinoin428 Nov 2025Not stated4/16
Propiomazine41 Dec 2025Not stated1/16
Buprenorphine31 Jul 2026Distribution or logistics4/16
Sertraline31 May 2026Not stated11/16
Hydroxyzine218 Sep 2026Regulatory or licensing2/16
Loratadine21 Jul 2026Not stated5/16
Methylphenidate21 Aug 2025Not stated9/16
Potassium Chloride21 Aug 2026Not stated5/16
Reboxetine22 Nov 2026Not stated3/16
Acetylsalicylic Acid116 Apr 2026Manufacturing problem4/16
Adapalene, Combinations11 Nov 2026Not stated2/16
Alimemazine119 Jun 2026Manufacturing problem2/16
Alitretinoin117 Sep 2026Other1/16
Allopurinol121 Oct 2026Not stated9/16
Amitriptyline126 Oct 2026Regulatory or licensing5/16
Atorvastatin113 Aug 2026Other11/16
Atorvastatin and Ezetimibe12 Jun 2025Not stated6/16
Calcium Carbonate16 Oct 2026Manufacturing problem1/16
Chlorzoxazone11 Nov 2026Not stated1/16
Ciprofloxacin114 Oct 2025Not stated2/16
Combinations115 Oct 2026Not stated1/16
Deferoxamine115 Jul 2026Not stated3/16
Diatrizoic Acid16 Mar 2026Not stated5/16
Diazepam11 Nov 2026Not stated7/16
Drospirenone and Estrogen119 Oct 2026Other2/16
Esomeprazole115 Nov 2026Not stated9/16
Ganirelix11 Nov 2026Not stated5/16
Ibuprofen115 Jul 2026Not stated8/16
Levodopa and Decarboxylase Inhibitor11 May 2026Not stated4/16
Loperamide11 Aug 2026Not stated6/16
Metoclopramide130 Oct 2026Distribution or logistics6/16
Opium Derivatives and Expectorants122 Jun 2026Regulatory or licensing2/16
Piracetam113 Jul 2026Not stated1/16
Quetiapine126 Jan 2026Other12/16
Raloxifene11 May 2025Commercial decision or withdrawal3/16
Saxagliptin18 Dec 2025Commercial decision or withdrawal2/16
Tamoxifen11 Oct 2026Not stated4/16
Tramadol11 Sep 2025Not stated7/16
Tranexamic Acid126 May 2026Not stated10/16
Vinorelbine11 Oct 2026Not stated5/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.